1 enrolling by invitation, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow AvenCell Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123 - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Enrolling by invitation | AvenCell Therapeutics, Inc. | 178 | 2026-01-29 | 2026-03-16 | |
| Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T - Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma | Phase 1 / Phase 2 | Recruiting | AvenCell Therapeutics, Inc. | 178 | 2026-01-06 | 2026-08-28 |
Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Prostatic Neoplasms (1)
Cyclophosphamide (1) · Inosine Monophosphate (1) · fludarabine (1)
Germany (2) · United States (1)
2025 (1)